Daily subcutaneous injection of low-dose interleukin 2 expands natural killer cells in vivo without significant toxicity

We aimed to determine the toxicity and immunological effects of daily s.c. administered low-dose interleukin (IL) 2. Adult cancer patients received a single daily s.c. injection of IL-2 as outpatients for 90 consecutive days. Cohorts of four to nine patients were treated at escalating IL-2 dose leve...

Full description

Saved in:

Bibliographic Details
Published in:	Clinical cancer research Vol. 2; no. 4; pp. 669 - 677
Main Authors:	MEROPOL, N. J, PORTER, M, CALIGIURI, M. A, BLUMENSON, L. E, LINDEMANN, M. J, PEREZ, R. P, VAICKUS, L, LOEWEN, G. M, CREAVEN, P. J, WILKES, K. A, GIEDLIN, M. A
Format:	Journal Article
Language:	English
Published:	Philadelphia, PA American Association for Cancer Research 01-04-1996
Subjects:	Adult Aged Antineoplastic agents Biological and medical sciences Humans Immunotherapy Injections, Subcutaneous Interleukin-2 - administration & dosage Interleukin-2 - adverse effects Killer Cells, Natural - drug effects Killer Cells, Natural - immunology Medical sciences Middle Aged Neoplasms - immunology Neoplasms - therapy Pharmacology. Drug treatments Antineoplastic agent Human Immune response Low dose Cytokine Cellular immunity Malignant tumor Natural killer cell Immunostimulant agent Treatment Interleukin 2 Immunotherapy Phase I trial Subcutaneous administration Daily dose
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	We aimed to determine the toxicity and immunological effects of daily s.c. administered low-dose interleukin (IL) 2. Adult cancer patients received a single daily s.c. injection of IL-2 as outpatients for 90 consecutive days. Cohorts of four to nine patients were treated at escalating IL-2 dose levels until the maximum tolerated dose (MTD) was defined. Peripheral blood mononuclear cell phenotyping, IL-2 serum levels, and the presence of anti-IL-2 antibodies were investigated. Thirty-eight patients were treated at seven IL-2 dose levels ranging from 0.4 to 1.75 million International Units (mIU)/m2 daily. The MTD was 1.25 mIU/m2, with constitutional side effects, vomiting, and hyperglycemia dose limiting. Severe toxicity did not occur at or below the MTD, although mild local skin reaction and mild constitutional side effects were common. Objective tumor regressions were not observed during this Phase I trial. Low-dose IL-2 resulted in natural killer (NK) cell (CD3(-) CD56(+)) expansion at all dose levels. This effect was dose dependent (P < 0.01), ranging from a 154 to 530% increase over baseline. Peak NK levels were achieved at 6-8 weeks and sustained through 12 weeks of therapy. As predicted by in vitro studies of IL-2 receptor structure-activity relationships, the subset of NK cells that constitutively express high-affinity IL-2 receptors (CD3(-)CD56(bright+)) showed more profound dose-dependent expansion, with increases ranging from 368 to 2763% (P = 0.015). NK expansion occurred at peak IL-2 levels <10 pM (2.3 IU/ml). Three patients developed nonneutralizing anti-IL-2 antibodies. Thus, we concluded that selective expansion of NK cells may be achieved in vivo with daily s.c. injections of low-dose IL-2 with minimal toxicity.
ISSN:	1078-0432 1557-3265